Thus, our findings of the chemokine-receptor-associating molecule FROUNT as a new class of target to control tumor-promoting macrophages, and the inhibitory activity of the old drug disulfiram against FROUNT function, provides an effective therapeutic option in cancer treatment, focusing on intracellular chemokine signaling molecules. This evidence concerns the gene NUP85 and neoplasm.